Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drug Allergy Clear all
Recruiting Phase 3 Interventional

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581
View directory record Official record
Conditions
Asthma
Interventions
PF-07275315, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Results available

Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD

NCT01542372
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Medication augmentation, CBT
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
43 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

NCT03257995
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol maleate, Indacaterol acetate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 28, 2026, 11:10 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Effect of Chinese Herbal Medicine on Food Allergy

NCT00602160
View directory record Official record
Conditions
Food Allergy
Interventions
FAHF-2 (TM)
Drug
Lead sponsor
Li, Xiu-Min, M.D.
Individual
Eligibility
12 Years to 45 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Oct 28, 2026, 11:10 PM EDT
Terminated No phase listed Observational Results available

Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease

NCT01320072
View directory record Official record
Conditions
Asthma, Aspirin-induced
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 28, 2026, 11:10 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Cyclosporine Vs Steroids in DRESS

NCT04988256
View directory record Official record
Conditions
DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions
Cyclosporine, Methylprednisolone and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 28, 2026, 11:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

NCT02037347
View directory record Official record
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions
Palifermin
Drug
Lead sponsor
Brett King
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 28, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

NCT00751101
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
Interventions
Nicotine patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 28, 2026, 11:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions

NCT07605806
View directory record Official record
Conditions
Healthy Volunteer, Hypersensitivity Reactions, Vancomycin
Interventions
Vancomycin (IV)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

NCT00987233
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
triamcinolone acetonide aqueous nasal spray (Apotex Inc.), triamcinolone acetonide aqueous nasal spray (Nasacort® AQ), Placebo
Drug
Lead sponsor
Apotex Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 28, 2026, 11:10 PM EDT
Completed No phase listed Observational

ParentLink: Better and Safer Emergency Care for Children

NCT00457600
View directory record Official record
Conditions
Otitis Media, Urinary Tract Infection, Asthma, Head Injury
Interventions
patient-driven health IT product
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 12 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2007 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

NCT06780332
View directory record Official record
Conditions
Phenylketonuria, PKU
Interventions
RDD to Palynziq
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chevy Chase, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

AdheRence to Inhaled Corticosteroids in Asthma

NCT03769519
View directory record Official record
Conditions
Medication Adherence, Asthma
Interventions
ARICA
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 28, 2026, 11:10 PM EDT
Withdrawn Not applicable Interventional

Smartphone-facilitated Asthma Control

NCT02205723
View directory record Official record
Conditions
Childhood Asthma
Interventions
Asthma teaching in ER, Smartphone Asthma Control
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
4 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Functional Medicine in Asthma (FAst) Study

NCT02808689
View directory record Official record
Conditions
Asthma
Interventions
Lifestyle Factors, Customized use of Dietary Supplements, Currently Accepted Asthma Care Guidelines
Behavioral · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil

NCT01219023
View directory record Official record
Conditions
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Interventions
sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 28, 2026, 11:10 PM EDT
Not listed No phase listed Observational

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00897039
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
flow cytometry, immunohistochemistry staining method
Other
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 28, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT07216027
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Huntington Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951
View directory record Official record
Conditions
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
3 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

NCT00248248
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
liposomal doxorubicin
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840
View directory record Official record
Conditions
Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions
Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
Combination Product
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 28, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118690
View directory record Official record
Conditions
Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions
Fluticasone propionate/salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 17 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Jonesboro, Arkansas • East Artesia, California • Huntington Beach, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 28, 2026, 11:10 PM EDT